microscope 2

InMed Pharmaceuticals


CA$52.6m market cap

CA$0.31 last close

InMed is a biopharmaceutical company focused on manufacturing and developing cannabinoids. Its main pipeline product is INM-755 for epidermolysis bullosa, a serious, debilitating orphan indication.

Investment summary

InMed is a Canada-based biopharmaceutical company focused on maximizing the therapeutic potential of cannabinoids. Through its biosynthesis platform, the company believes it has distinct advantages over both naturally sourced and chemically synthesized cannabinoids, which could give it access to both the medical and retail markets, although the process is still in development. The company is also developing a proprietary pipeline, including INM-755 for epidermolysis bullosa (EB), a serious orphan indication, and expects to file a CTA for INM-755 in H219 with initiation of a 30 person Phase I by the end of the year.

Y/E Jun
Revenue (C$m)
PBT (C$m)
EPS (c)
P/E (x)
P/CF (x)
2017A 0.0 (3.3) (3.2) (3.27) N/A N/A
2018A 0.0 (5.5) (5.3) (3.74) N/A N/A
2019E 0.0 (9.0) (8.4) (4.92) N/A N/A
2020E 0.0 (14.0) (13.9) (7.79) N/A N/A
Last updated on 25/07/2019
Industry outlook

The market for cannabinoids, whether FDA-approved, medical or recreational is growing at a fantastic rate. Legal cannabis sales in the US alone were around $7.5 billion in 2017 and we expect it to grow to $28 billion by 2023.

Last updated on 25/07/2019
Share price graph
Balance sheet
Forecast net cash (C$m) 17.6
Forecast gearing ratio (%) N/A
Price performance
Actual (17.6) (33.0) (60.4)
Relative* (18.2) (32.6) (60.6)
52-week high/low C$1.0/C$0.3
*% relative to local index
Key management
Jeff Charpentier CFO
Eric Adams President & CEO
Josh Blacher Chief Business Officer